A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial aims to find out which type of imaging scan is better for detecting and tracking lobular breast cancer that has spread to other parts of the body, also known as metastatic lobular breast carcinoma. The study will compare two types of scans: one that uses a special substance called fluorine 18 (18F)-fluoroestradiol (FES) and another that uses fluorine 18-fluorodeoxyglucose (FDG). By doing this, researchers hope to determine which scan provides more accurate information for patients with this specific type of cancer.

To participate in this trial, individuals must be adults over 18 years old with confirmed metastatic lobular breast cancer that is hormone receptor-positive (ER+) and HER2-negative. They should have a good performance status, meaning they can carry out daily activities with minimal assistance, and their life expectancy should be at least 12 months. Participants can expect to undergo imaging scans and may receive additional monitoring throughout the study. It's important to note that certain health conditions or treatments may prevent someone from joining the trial, so discussing eligibility with a healthcare provider is essential.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient \> 18 years old
• • Biopsy-proven metastatic ILC
• • Confirmed ER+ breast cancer from either primary tumor or metastatic biopsy (ER receptor percent staining ≥ 10% of tumor cells by IHC)
• • HER2-negative per ASCO/CAP
• • ECOG Performance Status Score of 0, 1 or 2.
• • Patient can have received up to 2 lines of therapy in the metastatic setting
• • Life expectancy of at least 12 months
• Exclusion Criteria:
• • Low ER expression defined as ER \<10% of tumor cells by IHC
• • Patients who have been on adjuvant ER-blocking endocrine therapy with SERM or SERD without an 8- and 24-weeks washout, respectively. (The use of aromatase inhibitors or ovarian suppression is permitted given that they do not block estrogen receptors).
• • Pregnancy or lactation or parturient or nursing mother
• • Patient presents with any other clinically active, serious, life-threatening disease, medical, or psychiatric condition, and/or who has a life expectancy of \<12 months, or for whom study participation may compromise their management; and/or a patient who the investigator judges to be unsuitable for participation in the study for any reason.